All Stories

  1. Clinical outcomes of hypertriglyceridemia-associated acute pancreatitis: a prospective multicenter Italian cohort
  2. Neuropathic Pain in Pancreatic Cancer: An Update of the Last Five Years
  3. Editorial for “Does Training in LI‐RADS Version 2018 Improve Readers' Agreement With the Expert Consensus and Inter‐Reader Agreement in MRI Interpretation?”
  4. Diagnosis and Treatment of Acute Pancreatitis Due to Hypertriglyceridemia in Italy: A Survey among Physicians of the Italian Association for the Study of the Pancreas: A Brief Report
  5. The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency
  6. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
  7. Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency
  8. Epidemiology, clinical features and diagnostic work-up of cystic neoplasms of the pancreas: Interim analysis of the prospective PANCY survey
  9. Genome‐wide association study identifies an early onset pancreatic cancer risk locus
  10. Evaluation and validation of the prognostic value of nutrition and immunity parameters in gastric cancer after R0 resection
  11. Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer
  12. Gossypibomas as a rare cause of common bile duct dilation
  13. Acute Pancreatitis Associated With Myotonic Dystrophy Type I
  14. The Clinical Impact of Splanchnic Ischemia on Patients Affected by Thoracoabdominal Aortic Aneurysms Treated with Fenestrated and Branched Endografts
  15. Alcohol-related chronic exocrine pancreatic insufficiency: diagnosis and therapeutic management. A proposal for treatment by the Italian Association for the Study of the Pancreas (AISP) and the Italian Society of Alcohology (SIA)
  16. A rare cause of melena in lung cancer
  17. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry
  18. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma
  19. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients
  20. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study
  21. Role of BAG3 in cancer progression: A therapeutic opportunity
  22. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma
  23. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer
  24. Endoscopic ultrasonography in chronic asymptomatic pancreatic hyperenzymemia: Why not?
  25. Levels of uric acid in erectile dysfunction of different aetiology
  26. Pancreatic enzyme replacement therapy after gastric resection: An update
  27. Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study
  28. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation
  29. Comparison of Clinical Data and Scores of Quality of Life, Anxiety, and Depression in Patients With Different Types of Intraductal Papillary Mucinous Neoplasms
  30. Response to Malleo et al.
  31. Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management
  32. Serum endocannabinoids in assessing pain in patients with chronic pancreatitis and in those with pancreatic ductal adenocarcinoma
  33. Endoscopic Ultrasonography May Select Subjects Having Asymptomatic Chronic Pancreatic Hyperenzymemia Who Require a Stricter Follow-up
  34. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival
  35. Levels of l -arginine and l -citrulline in patients with erectile dysfunction of different etiology
  36. Benign Exocrine Pancreatic Diseases in Inflammatory Bowel Diseases
  37. Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery
  38. The Health Gain Obtainable from Pancreatic Resection for Adenocarcinoma in the Elderly
  39. Can Serum Pancreatic Amylase and Lipase Levels Be Used as Diagnostic Markers to Distinguish Between Patients With Mucinous Cystic Lesions of the Pancreas, Chronic Pancreatitis, and Pancreatic Ductal Adenocarcinoma?
  40. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes
  41. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients
  42. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
  43. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk
  44. A comprehensive analysis on expected years of life lost due to pancreatic cancer
  45. Are we ready for early discharge of patients with mild non-alcoholic acute interstitial pancreatitis?
  46. Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy
  47. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review
  48. Implications and issues related to familial pancreatic cancer: a cohort study of hospitalized patients
  49. Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer
  50. Corrigendum
  51. Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
  52. Quality assessment of the guidelines on cystic neoplasms of the pancreas
  53. Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer
  54. Consensus guidelines on severe acute pancreatitis
  55. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer
  56. TERTgene harbors multiple variants associated with pancreatic cancer susceptibility
  57. Serum Markers of Myocardial Damage in Acute Pancreatitis
  58. Branch-Type Intraductal Papillary Mucinous Neoplasm of the Pancreas
  59. Quality of life in patients with long-standing chronic non-pathological pancreatic hyperenzymemia
  60. Enlarged pancreas: not always a cancer
  61. Evaluation of High Sensitive Troponin in Erectile Dysfunction
  62. Exocrine Pancreas Involvement in Celiac Disease: A Review
  63. Vitamin D and Erectile Dysfunction
  64. Different reconstruction techniques after pancreatoduodenectomy do not affect clinical and patient reported outcomes
  65. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer
  66. Antioxidant Treatment for Acute Pancreatitis
  67. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms
  68. Clasificación Internacional y Multidisciplinaria de la Pancreatitis Aguda: Edición española 2013
  69. Immunosuppressive drugs for the treatment of autoimmune pancreatitis
  70. Antioxidants Are Not Useful in Reducing Both Pain and Inflammation in Chronic Pancreatitis
  71. Five-year overview: an update on enteral nutrition and refeeding strategy in acute pancreatitis
  72. Three-Dimensional Contrast-Enhanced Ultrasonography of Intraductal Papillary Mucinous Neoplasms of the Pancreas
  73. Long term outcome of acute pancreatitis in Italy: Results of a multicentre study
  74. BAG3 Is a Novel Serum Biomarker for Pancreatic Adenocarcinomas
  75. Contrast-Enhanced Ultrasound in the Differential Diagnosis of Exocrine Versus Neuroendocrine Pancreatic Tumors
  76. Outcomes of intraductal papillary mucinous neoplasm with “Sendai-positive” criteria for resection undergoing non-operative management
  77. Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas
  78. Einteilung des Schweregrads der akuten Pankreatitis
  79. Risk Factors for Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: A Multicentre Case–Control Study
  80. Is troponin T a useful marker of myocardial damage in acute pancreatitis? A prospective time course study
  81. ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium
  82. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension
  83. Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium
  84. Exocrine pancreatic insufficiency in adults: A shared position statement of the Italian association for the study of the pancreas
  85. Is diabetes mellitus a risk factor for pancreatic cancer?
  86. Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations
  87. Determinant-Based Classification of Acute Pancreatitis Severity
  88. Acute recurrent pancreatitis and pancreas divisum: Appearances can be deceiving
  89. Expression of the Antiapoptotic Protein BAG3 Is a Feature of Pancreatic Adenocarcinoma and Its Overexpression Is Associated With Poorer Survival
  90. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
  91. Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis
  92. Serum Amyloid A and C-Reactive Protein Independently Predict the Recurrences of Atrial Fibrillation After Cardioversion in Patients With Preserved Left Ventricular Function
  93. Circulating Lymphocyte Subsets in Pancreatic Adenocarcinoma and Their Relationship to the Stage of the Disease
  94. Selecting families eligible for pancreatic cancer screening: Another brick in the wall for the early detection of pancreatic ductal adenocarcinoma and its precursors
  95. Treating pain in chronic pancreatitis—is the dilemma over?
  96. Autoimmune pancreatitis management: reflections on the past decade and the decade to come
  97. Preoperative Gemcitabine and Oxaliplatin in a Patient with Ovarian Metastasis from Pancreatic Cystadenocarcinoma
  98. Pancreatic ductal adenocarcinoma screening: New perspectives
  99. Usefulness of the Clavien-Dindo classification after pancreaticoduodenectomy
  100. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders
  101. Clinical and Patient-Reported Outcomes After Pancreatoduodenectomy for Different Diseases
  102. Therapeutic management and clinical outcome of autoimmune pancreatitis
  103. The usefulness of a grading system for complications resulting from pancreatic resections: a single center experience
  104. Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
  105. Is the pancreas affected in patients with septic shock? — a prospective study
  106. Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases
  107. Radiofrequency Ablation for Advanced Ductal Pancreatic Carcinoma
  108. Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study
  109. Cystic dystrophy of the duodenal wall is not always associated with chronic pancreatitis
  110. Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
  111. Does Ablation Technique Utilized in the Management of Unresectable Locally Advanced Pancreatic Adenocarcinoma?
  112. Practical Guidelines for Acute Pancreatitis
  113. Italian consensus guidelines for chronic pancreatitis
  114. Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study
  115. Spontaneous Cholecystocutaneous Fistula
  116. Pancreatic Endocrine Tumors Less Than 4 cm in Diameter
  117. Total pancreatectomy: indications, operative technique, and results
  118. The Problems of Radiofrequency Ablation as an Approach for Advanced Unresectable Ductal Pancreatic Carcinoma
  119. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection
  120. Clinical Outcome of Patients Who Underwent Total Pancreatectomy
  121. Warm Water and Oil Assistance in Colonoscopy
  122. Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?
  123. NSAIDs and Acute Pancreatitis: A Systematic Review
  124. ORIGINAL RESEARCH—ERECTILE DYSFUNCTION: Evaluation of Microalbuminuria in Patients with Erectile Dysfunction
  125. Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors
  126. Pancreatic and extrapancreatic lesions in patients with intraductal papillary mucinous neoplasms of the pancreas: a single-centre experience
  127. Serum and Urine Trypsinogen Activation Peptide in Assessing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
  128. Abdominal pain and ECG alteration: a simple diagnosis?
  129. The concept of autoimmune pancreatitis and its immunological backgrounds
  130. Water-related techniques in colonoscopy: the end justifies the means!
  131. Pharmacotherapy for acute pancreatitis
  132. Alcoholic Pancreatitis: Pathogenesis, Incidence and Treatment with Special Reference to the Associated Pain
  133. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms
  134. Painless Jaundice: Remember Alcohol and Smoking Habits for the Diagnosis
  135. Value of Both WHO and TNM Classification Systems for Patients with Pancreatic Endocrine Tumors: Results of a Single-Center Series
  136. Evaluation of Patient-Reported Outcome in Subjects Treated Medically for Acute Pancreatitis: A Follow-Up Study
  137. Patient-reported outcomes in patients with endocrine tumors of the ileum
  138. Sclerosing Cholangitis, Autoimmune Chronic Pancreatitis, and Situs Viscerum Inversus Totalis
  139. Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients
  140. Effect of early antibiotic prophylaxis with ertapenem and meropenem in experimental acute pancreatitis in rats
  141. Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: A prospective study
  142. Chronic pancreatitis: Maldigestion, intestinal ecology and intestinal inflammation
  143. Etiology of chronic pancreatitis: Has it changed in the last decade?
  144. Is asymptomatic pancreatic hyperenzymemia the same condition in adults and in children?
  145. Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas
  146. Usefulness of serum IgG4 in the diagnosis and follow up of autoimmune pancreatitis: A systematic literature review and meta-analysis
  147. Sedation on demand and lubrication during colonoscopy: should we change our minds?
  148. Diagnosis and treatment of acute pancreatitis: The position statement of the Italian Association for the study of the pancreas
  149. Hepatobiliary and pancreatic: Caroli's disease
  150. SPINK1 and PRSS1 Mutations in Benign Pancreatic Hyperenzymemia
  151. Serum Adhesion Molecules in Acute Pancreatitis
  152. Upper endoscopy and tongue piercing: please, take care of the endoscope!
  153. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs
  154. Warm Water or Oil-Assisted Colonoscopy: Toward Simpler Examinations?
  155. Serous Cystic Tumors of the Pancreas: When to Observe and When to Operate
  156. Acute recurrent pancreatitis: An autoimmune disease?
  157. Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires
  158. Sedation during colonoscopy and the benefits of lubrication
  159. Fecal Calprotectin Levels in Patients with Colonic Polyposis